Novel pharmacology of cannabidivarin, tetrahydrocannabivarin, cannabigerol, and cannabichromene in vitro and in vivo

被引：0
|
作者：
Laprairie, Robert [1 ]
Mohamed, Kawthar [1 ]
Kim, David [1 ]
Zagzoog, Ayat [1 ]
机构：
[1] Univ Saskatchewan, Saskatoon, SK, Canada
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2020年 / 177卷 / 11期
关键词：
THC;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P228
引用
收藏
页码：2626 / 2627
页数：2
相关论文
共 50 条
  • [1] Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ9-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues
    Piscitelli, Fabiana
    Pagano, Ester
    Lauritano, Anna
    Izzo, Angelo A.
    Di Marzo, Vincenzo
    ANALYTICAL CHEMISTRY, 2017, 89 (08) : 4749 - 4755
  • [2] In vivo and in vitro pharmacology of epibatidine
    Lembeck, F
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (04) : 113 - 113
  • [3] In Vitro and In Vivo Anti-Inflammatory Potential of Cannabichromene Isolated from Hemp
    Hong, Min
    Kim, Jong-Hui
    Han, Joon-Hee
    Ryu, Byeong-Ryeol
    Lim, Young-Seok
    Lim, Jung-Dae
    Park, Sang-Hyuck
    Kim, Chang-Hyeug
    Lee, Soo-Ung
    Kwon, Tae-Hyung
    PLANTS-BASEL, 2023, 12 (23):
  • [4] In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists
    Marusich, Julie A.
    Gamage, Thomas F.
    Zhang, Yanan
    Akinfiresoye, Luli R.
    Wiley, Jenny L.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2022, 220
  • [5] THE IN VITRO AND IN VIVO PHARMACOLOGY OF NOVEL TMEM16A POTENTIATOR COMPOUNDS
    Danahay, H.
    Lilley, S.
    Charlton, H.
    Fox, R.
    Button, B.
    Sabater, J.
    Gosling, M.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S357 - S357
  • [6] Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
    Hill, Andrew J.
    Weston, Samantha E.
    Jones, Nicholas A.
    Smith, Imogen
    Bevan, Sarah A.
    Williamson, Elizabeth M.
    Stephens, Gary J.
    Williams, Claire M.
    Whalley, Benjamin J.
    EPILEPSIA, 2010, 51 (08) : 1522 - 1532
  • [7] In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist
    Stebbins, Karin J.
    Broadhead, Alex R.
    Cabrera, Geraldine
    Correa, Lucia D.
    Messmer, Davorka
    Bundey, Richard
    Baccei, Christopher
    Bravo, Yalda
    Chen, Austin
    Stock, Nicholas S.
    Prasit, Peppi
    Lorrain, Daniel S.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 809 : 130 - 140
  • [8] Novel, centrally active mGlu1 antagonists: In vitro and in vivo pharmacology
    Lesage, ASJ
    Bischoff, F
    Van Beijsterveldt, L
    Meert, T
    Steckler, T
    Ashton, D
    NEUROPHARMACOLOGY, 2002, 43 (02) : 295 - 295
  • [9] In vitro and in vivo pharmacology of UR-3216, a novel GPIIB/IIIA antagonist
    Baba, K
    Aga, Y
    Nakanishi, T
    Doi, M
    Matsuda, A
    Tanaka, M
    Motoyama, T
    Kuroki, Y
    Kita, J
    Ueno, H
    THROMBOSIS AND HAEMOSTASIS, 1999, : 670 - 670
  • [10] Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo
    Fleisher-Berkovich, Sigal
    Ventura, Yvonne
    Amoyal, Maya
    Dahan, Arik
    Feinshtein, Valeria
    Alfahel, Leenor
    Israelson, Adrian
    Bernstein, Nirit
    Gorelick, Jonathan
    Ben-Shabat, Shimon
    BIOMOLECULES, 2023, 13 (02)
12345